Table 3. Multivariate analysis between clinical variables and survival outcomes.
| Factors | PFS | OS | |||
|---|---|---|---|---|---|
| P value | HR (95% CI) | P value | HR (95% CI) | ||
| Age group (≥60 years) | 0.62 | 1.36 (0.4–4.63) | 0.53 | 1.68 (0.33–8.58) | |
| Gender (male) | 0.44 | 1.82 (0.4–8.31) | 0.45 | 2.17 (0.29–16.06) | |
| ECOG PS (=2) | 0.01 | 4.26 (1.41–12.92) | 0.64 | 0.75 (0.23–2.47) | |
| Hypertension as AE | 0.46 | 0.59 (0.14–2.40) | 0.23 | 2.8 (0.52–15.18) | |
| Proteinuria as AE | 0.30 | 2.43 (0.45–13.04) | 0.61 | 0.44 (0.02–10.24) | |
| Hand-foot syndrome as AE | 0.01 | 0.09 (0.01–0.62) | 0.16 | 0.19 (0.02–1.89) | |
| Mucositis oral as AE | 0.01 | 43.87 (2.22–866.43) | 0.77 | 1.66 (0.05–51.25) | |
| Fatigue as AE | 0.01 | 6.37 (1.71–23.71) | 0.83 | 1.18 (0.27–5.12) | |
PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; AE, adverse event.